Ozempic Approved By FDA For Chronic Kidney Disease Treatment

by THEFUTURE.TEAM

January 29, 2025

The U.S. Food and Drug Administration (FDA) has approved Ozempic for the treatment of patients with chronic kidney disease, marking a new milestone for Novo Nordisk’s highly popular drug, previously authorized for type 2 diabetes and weight loss.

Key Facts

The FDA approval allows Ozempic to be used to reduce the risk of kidney disease progression, kidney failure, and death from cardiovascular events in patients with type 2 diabetes and chronic kidney disease.
The approval is based on a late-stage trial involving more than 3,500 participants, which showed that Ozempic lowered the risk of kidney disease progression and death from kidney or cardiovascular complications by 24% compared to a placebo.
Patients using Ozempic also experienced slower rates of kidney decline, according to Novo Nordisk.

In December 2024, the European Union’s health regulators also gave the go-ahead for Novo Nordisk to expand Ozempic’s label, indicating that the drug could reduce the risk of chronic kidney disease-related events in adults with type 2 diabetes.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Surprising Fact

The Centers for Disease Control and Prevention (CDC) estimates that one in every three adults with diabetes suffers from chronic kidney disease. Diabetes, both type 1 and type 2, can impair kidney function due to its effects on the kidneys’ ability to filter waste, compounded by the high blood pressure that often accompanies the condition.

What Has Ozempic Been Approved For?

Ozempic has already been approved by the FDA for type 2 diabetes management, and it’s also widely used off-label for weight loss. Additionally, the FDA authorized Novo Nordisk’s Wegovy—which contains the same active ingredient, semaglutide—for weight loss and lowering the risk of cardiovascular events, such as heart attacks and strokes.

Key Background

Ozempic and Wegovy are part of the GLP-1 agonist class of medications, which mimic the function of a gut hormone responsible for regulating blood sugar and appetite. Research into the broader benefits of these drugs has been growing. For example, Eli Lilly’s Zepbound, a competitor, was recently approved for treating obesity and sleep apnea, after it was shown to significantly reduce apnea events in a clinical trial.

Other studies suggest GLP-1 drugs might also have potential applications in treating alcohol use disorder and improving mood, cognitive function, and symptoms in patients with conditions like Parkinson’s, Alzheimer’s, dementia, bipolar disorder, and anxiety.

The Future Forbes Realty Global Properties

Central Bank Of Cyprus Balance Sheet Reflects Strong Eurosystem Position

by THEFUTURE.TEAM

February 17, 2026

Overview Of Financial Stability

The Central Bank of Cyprus (CBC) has released its latest balance sheet, reaffirming its steadfast role within the Eurosystem. The balance sheet, featuring total assets and liabilities of €29.545 billion, underscores the institution’s stable financial posture at the close of January 2026.

Asset Allocation And Strategic Holdings

Governor Christodoulos Patsalides issued the balance sheet, which details the CBC’s asset composition under the Eurosystem framework. Notably, the bank’s gold and gold receivables amounted to €1.635 billion, providing a significant hedge and stability to its balance sheet. Additional asset categories include claims on non-euro area residents denominated in foreign currency at €1.099 billion, while claims on euro area residents in both foreign and domestic currency add further depth to its portfolio.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

The most substantial asset category, intra-Eurosystem claims, reached €19.438 billion, an indication of the CBC’s deep integration with its European counterparts. Furthermore, euro-denominated securities held by euro area residents contributed €6.587 billion. Despite a marked emphasis on these areas, lending to euro area credit institutions in monetary policy operations recorded no activity during the period.

Liability Structure And Monetary Policy Implications

On the liabilities side, banknotes in circulation contributed €3.218 billion. Liabilities to euro area credit institutions associated with monetary policy operations were notably the largest single category, totaling €17.636 billion. Supplementary liabilities included those to other euro area residents, which aggregated to €4.989 billion, with government liabilities playing a predominant role at €4.754 billion.

Other liability items, such as claims related to special drawing rights allocated by the International Monetary Fund at €494.193 million, and provisions of €596.571 million, further articulate the CBC’s exposure. Revaluation accounts stood at €1.643 billion, and overall capital and reserves were confirmed at €333.822 million, completing the picture of a well-capitalized institution.

Conclusive Insights And Strategic Alignment

The detailed breakdown illustrates the CBC’s sizeable intra-Eurosystem exposures, reinforcing its central role within Europe’s monetary landscape. With an asset-liability balance maintained at €29.545 billion, the CBC’s financial position remains robust, indicating a commitment to structural stability and strategic risk management.

This fiscal disclosure not only provides transparency into the CBC’s operations but also serves as a benchmark for comparative analysis among other central banks within the Eurosystem, highlighting the intricate balance between asset liquidity, regulatory oversight, and monetary policy imperatives.

Breaking news